ReviewPrzeglad menopauzalny = Menopause review2025
Regenerative capacity of mesenchymal stem cells in the management of Asherman syndrome - a systematic review and meta-analysis of clinical outcomes.
Review in Przeglad menopauzalny = Menopause review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Asherman Syndrome is a refractory gynecological disorder resulting from injury to the endometrium due to various causes. The treatment of choice is hysteroscopic adhesiolysis; however, recurrence rates remain high. Stem cell therapy has emerged as a promising approach for regenerating damaged endometrium in refractory cases. So, this study aims to assess the efficacy of mesenchymal stem cell therapy in refractory Asherman syndrome unresponsive to conventional treatment. Material and methods: The study involved the literature searched in PubMed, Embase and Google Scholar databases from inception to June 2024. We included pre- and postintervention studies. We excluded case reports, conference abstracts, articles without full texts and studies with animal trials. Women with primary or secondary infertility of the reproductive age group (aged 20-50 years) with AS (Grade I-IV) not responding to standard treatment (hysteroscopic adhesiolysis and hormonal therapy) were included. Primary outcome included pregnancy outcome and change in the endometrial thickness whereas secondary outcome included improvement in menstrual pattern. Results: We identified 382 studies from our constructive search strategy. Finally, 12 studies with 137 women met the inclusion criteria. Stem cell therapy has been associated with an increase in endometrial thickness; the standardised mean difference was 2.09 (95% CI: 1.4-2.7). It has also been shown to improve pregnancy rate with risk ratio (RR) of 9.35 (95% CI: 4.2-24.9) and live birth rate (RR - 5.870, 95% CI: 2.071-16.633). All the patients reported improvement in menstrual function. Conclusions: Stem cell therapy is safe and effective in improving endometrial thickness, menstrual function and pregnancy rate in women with refractory AS. However, given the limitations of our study, further studies with a large sample size are needed to validate the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.